@prefix : <http://www.transceleratebiopharmainc.com/LY246708/V1#> .
@prefix pr: <http://www.assero.co.uk/Protocol#> .
@prefix isoC: <http://www.assero.co.uk/ISO11179Concepts#> .
@prefix isoT: <http://www.assero.co.uk/ISO11179Types#> .
@prefix isoR: <http://www.assero.co.uk/ISO11179Registration#> .
@prefix isoI: <http://www.assero.co.uk/ISO11179Identification#> .
@prefix bo: <http://www.assero.co.uk/BusinessOperational#> .
@prefix bc: <http://www.assero.co.uk/BiomedicalConcept#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .

<http://www.transceleratebiopharmainc.com/LY246708/V1>
	rdf:type owl:Ontology ;
.
<http://www.assero.co.uk/EP#10ecde19-4168-4354-bc99-12a105131a22>
	rdf:type pr:Epoch ;
	isoC:label "Screening"^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/EP#9e2fa77a-a5ec-42a6-a1d8-b45405b0b31c>
	rdf:type pr:Epoch ;
	isoC:label "Treatment"^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#260786b3-0f7e-4456-b4a4-6b7cf359c65c>
	rdf:type pr:Arm ;
	isoC:label "High Dose"^^xsd:string ;
	pr:description "High Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "1"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#86370a06-7ac6-45eb-8540-de9d0123d26b>
	rdf:type pr:Arm ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:description "Low Dose"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "2"^^xsd:integer ;
.
<http://www.assero.co.uk/ARM#b2f27934-1e9a-4cda-944a-6dc1ef985f76>
	rdf:type pr:Arm ;
	isoC:label "Placebo"^^xsd:string ;
	pr:description "Placebo"^^xsd:string ;
	pr:armType ""^^xsd:string ;
	pr:ordinal "3"^^xsd:integer ;
.
<http://www.assero.co.uk/ELE#ef47d0f3-9b7b-4d57-b656-5af09b6f37b0>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#260786b3-0f7e-4456-b4a4-6b7cf359c65c> ;
	pr:inEpoch <http://www.assero.co.uk/EP#10ecde19-4168-4354-bc99-12a105131a22> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
.
<http://www.assero.co.uk/ELE#67eb0d00-1151-46c4-9354-e090ba7e88e6>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#86370a06-7ac6-45eb-8540-de9d0123d26b> ;
	pr:inEpoch <http://www.assero.co.uk/EP#10ecde19-4168-4354-bc99-12a105131a22> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
.
<http://www.assero.co.uk/ELE#5d9bcf79-86a5-4a94-a808-42db72ee3f81>
	rdf:type pr:Element ;
	isoC:label "Screen"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#b2f27934-1e9a-4cda-944a-6dc1ef985f76> ;
	pr:inEpoch <http://www.assero.co.uk/EP#10ecde19-4168-4354-bc99-12a105131a22> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
.
<http://www.assero.co.uk/ELE#f6d32c72-2f63-4bdc-8d86-e7c692cb6078>
	rdf:type pr:Element ;
	isoC:label "High Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#260786b3-0f7e-4456-b4a4-6b7cf359c65c> ;
	pr:inEpoch <http://www.assero.co.uk/EP#9e2fa77a-a5ec-42a6-a1d8-b45405b0b31c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/ELE#c5a9d022-ebd1-4d83-8d1f-7827eff35514>
	rdf:type pr:Element ;
	isoC:label "Low Dose"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#86370a06-7ac6-45eb-8540-de9d0123d26b> ;
	pr:inEpoch <http://www.assero.co.uk/EP#9e2fa77a-a5ec-42a6-a1d8-b45405b0b31c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/ELE#cc6d910b-3608-4975-a870-98aeef5ba70e>
	rdf:type pr:Element ;
	isoC:label "Placebo"^^xsd:string ;
	pr:inArm <http://www.assero.co.uk/ARM#b2f27934-1e9a-4cda-944a-6dc1ef985f76> ;
	pr:inEpoch <http://www.assero.co.uk/EP#9e2fa77a-a5ec-42a6-a1d8-b45405b0b31c> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:containsTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
:PR
	rdf:type pr:Protocol ;
	isoC:label "LY246708"^^xsd:string ;
	isoT:hasState :PR_RS ;
	isoT:hasIdentifier :PR_SI ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-20T07:44:38+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "H2Q-MC-LZZT"^^xsd:string ;
	pr:title "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimerâ€™s Disease."^^xsd:string ;
	pr:shortTitle "LY246708"^^xsd:string ;
	pr:studyPhase :PR_TUC3 ;
	pr:studyType :PR_TUC4 ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#260786b3-0f7e-4456-b4a4-6b7cf359c65c> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#86370a06-7ac6-45eb-8540-de9d0123d26b> ;
	pr:specifiesArm <http://www.assero.co.uk/ARM#b2f27934-1e9a-4cda-944a-6dc1ef985f76> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#10ecde19-4168-4354-bc99-12a105131a22> ;
	pr:specifiesEpoch <http://www.assero.co.uk/EP#9e2fa77a-a5ec-42a6-a1d8-b45405b0b31c> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#8da05dab-b59b-4ce0-9a83-bfc8ebaceafd> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#79c3174e-0b8f-468d-b981-615a8e6d8a22> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#a20c271d-41bd-4769-ab53-29d5723c2028> ;
	pr:specifiesObjective <http://www.assero.co.uk/PROBJ#5bd589e2-b99b-47ec-8841-517969a30a69> ;
.
:PR_RS
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
:PR_SI
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "LY246708"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
:PR_TUC3
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15601> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
:PR_TUC4
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99076/V55#C99076_C82639> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66735/V4#C66735_C15228> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "DS8500-A-U202"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-20T07:44:39+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "DS8500-A-U202"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_DIA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_M/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "DS8500"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/DS8500/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-20T07:44:39+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "CPT_TALib-RA-BWE_V002"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_RA/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_I/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "CPT TALIB RA BWE"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15600> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/CPT_TALIB_RA_BWE/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C16084> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR>
	rdf:type pr:Protocol ;
	isoC:label "FLU 001"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-20T07:44:39+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	pr:acronym "MADE UP ACRONYM"^^xsd:string ;
	pr:title "A made up protocol title"^^xsd:string ;
	pr:shortTitle "FLU 001"^^xsd:string ;
	pr:studyPhase <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3> ;
	pr:studyType <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4> ;
	pr:interventionModel <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1> ;
	pr:masking <http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2> ;
	pr:forIndication <http://www.transceleratebiopharmainc.com/IND_INF/V1#IND> ;
	pr:inTa <http://www.transceleratebiopharmainc.com/TA_V/V1#TA> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "FLU001"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC3>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C66737/V42#C66737_C15602> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC4>
	rdf:type bo:TucReference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.cdisc.org/C99077/V28#C99077_C98388> ;
	bo:context <http://www.cdisc.org/CT/V62#TH> ;
	bo:localLabel ""^^xsd:string ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS>
	rdf:type bc:Assessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	isoT:hasState <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS> ;
	isoT:hasIdentifier <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI> ;
	isoT:origin ""^^xsd:string ;
	isoT:changeDescription ""^^xsd:string ;
	isoT:creationDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoT:lastChangeDate "2020-04-20T07:44:38+02:00"^^xsd:dateTime ;
	isoT:explanatoryComment ""^^xsd:string ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10> ;
	bo:hasManaged <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_RS>
	rdf:type isoR:RegistrationState ;
	isoR:registrationStatus "Incomplete"^^xsd:string ;
	isoR:administrativeNote ""^^xsd:string ;
	isoR:effectiveDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:untilDate "2016-01-01T00:00:00+00:00"^^xsd:dateTime ;
	isoR:unresolvedIssue ""^^xsd:string ;
	isoR:administrativeStatus ""^^xsd:string ;
	isoR:previousState "Incomplete"^^xsd:string ;
	isoR:multipleEdit "false"^^xsd:boolean ;
	isoR:byAuthority <http://www.assero.co.uk/RA#DUNS079658684> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_SI>
	rdf:type isoI:ScopedIdentifier ;
	isoI:identifier "ASS DAD"^^xsd:string ;
	isoI:versionLabel ""^^xsd:string ;
	isoI:version "1"^^xsd:positiveInteger ;
	isoI:semanticVersion "0.1.0"^^xsd:string ;
	isoI:hasScope <http://www.assero.co.uk/NS#TRANSCELERATE> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R1>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "1"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105183/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R2>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "2"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105181/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R3>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "3"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105171/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R4>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "4"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105204/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R5>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "5"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105199/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R6>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "6"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105173/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R7>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "7"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105202/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R8>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "8"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105203/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R9>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "9"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105172/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R10>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "10"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105185/V1#BCI> ;
.
<http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS_R11>
	rdf:type bo:Reference ;
	isoC:label ""^^xsd:string ;
	bo:enabled "true"^^xsd:boolean ;
	bo:optional "false"^^xsd:boolean ;
	bo:ordinal "11"^^xsd:positiveInteger ;
	bo:reference <http://www.s-cubed.dk/DAD_C105178/V1#BCI> ;
.
<http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38>
	rdf:type pr:Visit ;
	isoC:label "Baseline"^^xsd:string ;
	pr:shortName "BL"^^xsd:string ;
.
<http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123>
	rdf:type pr:Visit ;
	isoC:label "Week 8"^^xsd:string ;
	pr:shortName "Wk8"^^xsd:string ;
.
<http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e>
	rdf:type pr:Visit ;
	isoC:label "Week 12"^^xsd:string ;
	pr:shortName "Wk12"^^xsd:string ;
.
<http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83>
	rdf:type pr:Visit ;
	isoC:label "Week 16"^^xsd:string ;
	pr:shortName "Wk16"^^xsd:string ;
.
<http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292>
	rdf:type pr:Visit ;
	isoC:label "Week 24"^^xsd:string ;
	pr:shortName "Wk24"^^xsd:string ;
.
<http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3>
	rdf:type pr:Timepoint ;
	isoC:label "TP1"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#3eebceac-03e6-42fd-8606-f045fe62dd72> ;
	pr:inVisit <http://www.assero.co.uk/VI#cde782be8b675144b1c3a413d952e5058ca53d38> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#c5832c2e-7fee-4ee3-98d5-373fbfa3303c> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#bc06edbb-b0c1-43ec-96e8-0bcaab90e89c> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#36fd3d19-34c4-4259-9e51-1725f12fe63b> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#4282fcbe-be4d-4e68-bd4c-2db63b063b52> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#6ee193e1-603a-488e-9e30-bcde2252f676> ;
.
<http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963>
	rdf:type pr:Timepoint ;
	isoC:label "TP2"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#b42cdc12-1b82-495c-90f9-49f6c77901bf> ;
	pr:inVisit <http://www.assero.co.uk/VI#e96a2145277171a0c3f5deddef4f400c2e693123> ;
	pr:hasPlanned <http://www.assero.co.uk/STA#5fd057ee-7a85-4091-8aaf-daccb9f7c1ad> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#10e74c97-d2e1-4247-9680-26cb2ab7aaa3> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#2f634b77-cfc8-4d6c-8f38-c545de850c62> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#f758bfda-9a6c-42bf-96ef-e7a9df146ea5> ;
.
<http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be>
	rdf:type pr:Timepoint ;
	isoC:label "TP3"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#14265ea7-5f09-4143-bebe-061d9417e901> ;
	pr:inVisit <http://www.assero.co.uk/VI#4d7196ccd76ee7d4b198c45b837180508d93f61e> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#19805077-3323-43f2-ba38-ab20918f66d5> ;
.
<http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050>
	rdf:type pr:Timepoint ;
	isoC:label "TP4"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#d330eb17-6628-49c7-9126-6c568661bff0> ;
	pr:inVisit <http://www.assero.co.uk/VI#22b0f0c8d6218cbc9e10ab1b91c9e1f800cb4f83> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#e3d8f963-604f-40d6-899f-f5c49ae12195> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#82d3ea68-c930-4847-9181-cea0992f021e> ;
.
<http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703>
	rdf:type pr:Timepoint ;
	isoC:label "TP5"^^xsd:string ;
	pr:atOffset <http://www.assero.co.uk/IC#92a20b73-6750-4f02-93ca-5a7dd9c9070c> ;
	pr:inVisit <http://www.assero.co.uk/VI#409a2e79a0b954569269055689ebe4053add5292> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#3d918e9f-a979-4afb-bf2f-8e2e4d66f7c2> ;
	pr:hasPlanned <http://www.assero.co.uk/STFRM#3026fe6d-f707-477b-988c-e827c415a022> ;
.
<http://www.assero.co.uk/IC#3eebceac-03e6-42fd-8606-f045fe62dd72>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "0"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#b42cdc12-1b82-495c-90f9-49f6c77901bf>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "4838400"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#14265ea7-5f09-4143-bebe-061d9417e901>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "7257600"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#d330eb17-6628-49c7-9126-6c568661bff0>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "9676800"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/IC#92a20b73-6750-4f02-93ca-5a7dd9c9070c>
	rdf:type pr:TimepointOffset ;
	isoC:label ""^^xsd:string ;
	pr:windowOffset "14515200"^^xsd:integer ;
	pr:windowMinus "0"^^xsd:integer ;
	pr:windowPlus "0"^^xsd:integer ;
	pr:unit "Week"^^xsd:string ;
.
<http://www.assero.co.uk/PROBJ#8da05dab-b59b-4ce0-9a83-bfc8ebaceafd>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ1"^^xsd:string ;
	pr:fullText "To assess the effect of Xanomeline Transdermal Therapeutic System (TTS) on the ADAS-Cog and CIBIC+ scores at Week 24 in participants with Mild to Moderate Alzheimerâ€™s Disease"^^xsd:string ;
	pr:derivedFromObjective <http://www.transceleratebiopharmainc.com/OBJ_1/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#403aaffc-a411-4679-9fc8-6b2fc6d42035> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#48b71a65-e409-430a-9193-71a9b6e42351> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
.
<http://www.assero.co.uk/PROBJ#79c3174e-0b8f-468d-b981-615a8e6d8a22>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ2"^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas"^^xsd:string ;
	pr:derivedFromObjective <http://www.transceleratebiopharmainc.com/OBJ_3/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#43a8efb8-4e11-4ce8-9237-3c49be03671b> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#a9a96ec019494d5b8b041c1d2468061ae66e35d5> ;
.
<http://www.assero.co.uk/PROBJ#a20c271d-41bd-4769-ab53-29d5723c2028>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ3"^^xsd:string ;
	pr:fullText "To document the safety profile of the xanomeline TTS."^^xsd:string ;
	pr:derivedFromObjective <http://www.transceleratebiopharmainc.com/OBJ_4/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#ae77b643-475f-43ff-80ed-d27e89ea44f3> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#3d23ae45-fa3d-4021-8f08-649538a8a452> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#2a8f5af8-2f00-45d8-bafd-6d61b8a9485f> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#09353948-5092-4709-acda-d0704285415d> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
.
<http://www.assero.co.uk/PROBJ#5bd589e2-b99b-47ec-8841-517969a30a69>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ4"^^xsd:string ;
	pr:fullText "To assess the effect of xanomeline TTS on the measure of behavioral/neuropsychiatric symptoms in participants with  Alzheimerâ€™s Disease"^^xsd:string ;
	pr:derivedFromObjective <http://www.transceleratebiopharmainc.com/OBJ_5/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#4045ed58-9521-4410-a491-951cceecc5d4> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
.
<http://www.assero.co.uk/PROBJ#209ce10d-82b8-436f-934a-5f7c92ed8440>
	rdf:type pr:ProtocolObjective ;
	isoC:label "LY246708 OBJ5"^^xsd:string ;
	pr:fullText "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas"^^xsd:string ;
	pr:derivedFromObjective <http://www.transceleratebiopharmainc.com/OBJ_6/V1#OB> ;
	pr:isAssessedBy <http://www.assero.co.uk/PREND#3f1f57c5-b995-418e-bb04-d1cdb8fa7b43> ;
	pr:objectiveType <http://www.assero.co.uk/ENUM#025de599ea0a6262eeb4ea073413e273d0ea875b> ;
.
<http://www.assero.co.uk/PREND#403aaffc-a411-4679-9fc8-6b2fc6d42035>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP1"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Alzheimerâ€™s Disease Assessment Scale â€“ Cognitive Assessment (ADAS-Cog) 14 total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_1/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/PREND#48b71a65-e409-430a-9193-71a9b6e42351>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP2"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8, 16 and 24 in the Clinicianâ€™s Interview-Based Impression of Change plus caregiver input (CIBIC+)"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_2/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/PREND#43a8efb8-4e11-4ce8-9237-3c49be03671b>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP3"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
.
<http://www.assero.co.uk/PREND#ae77b643-475f-43ff-80ed-d27e89ea44f3>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP4"^^xsd:string ;
	pr:fullText "The proportion of participants with adverse events, serious adverse events (SAEs), and adverse events leading to study intervention discontinuation over the 24-week study intervention period"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_5/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/PREND#3d23ae45-fa3d-4021-8f08-649538a8a452>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP5"^^xsd:string ;
	pr:fullText "The change from baseline to Week 12 in continuous laboratory tests: Hepatic Function Panel"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_6/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be> ;
.
<http://www.assero.co.uk/PREND#2a8f5af8-2f00-45d8-bafd-6d61b8a9485f>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP6"^^xsd:string ;
	pr:fullText "The proportion of participants with abnormal (high or low) laboratory measures (urinalysis) during the postrandomization phase"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_7/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0f9f12d9-7fac-4e98-afaa-e980994139be> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#7bcbb7e5-72e5-470b-a671-027f93db9050> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#3ae66c5b-3f17-4c0a-88b3-24ad7463b703> ;
.
<http://www.assero.co.uk/PREND#09353948-5092-4709-acda-d0704285415d>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP7"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in ECG parameter: QTcF"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_8/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
.
<http://www.assero.co.uk/PREND#4045ed58-9521-4410-a491-951cceecc5d4>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP8"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the Neuropsychiatric Inventory (NPI) total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
.
<http://www.assero.co.uk/PREND#3f1f57c5-b995-418e-bb04-d1cdb8fa7b43>
	rdf:type pr:ProtocolEndpoint ;
	isoC:label "LY246708 EP9"^^xsd:string ;
	pr:fullText "The change from baseline to Week 8 in the DAD total score"^^xsd:string ;
	pr:derivedFromEndpoint <http://www.transceleratebiopharmainc.com/EP_9/V1#END> ;
	pr:primaryTimepoint <http://www.assero.co.uk/TP#439df9a4-42f4-4320-b80d-fac4202a47d3> ;
	pr:secondaryTimepoint <http://www.assero.co.uk/TP#0647eaa9-f94d-4f0d-a7fd-89ee08163963> ;
.
<http://www.assero.co.uk/STA#c5832c2e-7fee-4ee3-98d5-373fbfa3303c>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STA#5fd057ee-7a85-4091-8aaf-daccb9f7c1ad>
	rdf:type pr:StudyAssessment ;
	isoC:label "Disability Assessment for Dementia (DAD)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/ASS_DAD/V1#ASS> ;
.
<http://www.assero.co.uk/STFRM#bc06edbb-b0c1-43ec-96e8-0bcaab90e89c>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#10e74c97-d2e1-4247-9680-26cb2ab7aaa3>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#e3d8f963-604f-40d6-899f-f5c49ae12195>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#3d918e9f-a979-4afb-bf2f-8e2e4d66f7c2>
	rdf:type pr:StudyForm ;
	isoC:label "Clinician's Interview-Based Impression of Change (CIBIC+) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_CIBIC/V1#F> ;
.
<http://www.assero.co.uk/STFRM#36fd3d19-34c4-4259-9e51-1725f12fe63b>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#2f634b77-cfc8-4d6c-8f38-c545de850c62>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#82d3ea68-c930-4847-9181-cea0992f021e>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#3026fe6d-f707-477b-988c-e827c415a022>
	rdf:type pr:StudyForm ;
	isoC:label "Disability Assessment For Dementia (DAD) (Pilot)"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_DAD/V1#F> ;
.
<http://www.assero.co.uk/STFRM#4282fcbe-be4d-4e68-bd4c-2db63b063b52>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#19805077-3323-43f2-ba38-ab20918f66d5>
	rdf:type pr:StudyForm ;
	isoC:label "Laboratory Samples"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_LAB_SAMPLES/V1#F> ;
.
<http://www.assero.co.uk/STFRM#6ee193e1-603a-488e-9e30-bcde2252f676>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.
<http://www.assero.co.uk/STFRM#f758bfda-9a6c-42bf-96ef-e7a9df146ea5>
	rdf:type pr:StudyForm ;
	isoC:label "ECG Measurements"^^xsd:string ;
	pr:isDerivedFrom <http://www.transceleratebiopharmainc.com/F_ECG/V1#F> ;
.